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4 this legislation, in order to label a product gluten-free, the ingredients derived from gluten-containing cereals 92 must have been processed to reduce the gluten content or these ingredients must have been replaced by gluten-93 free cereals. There is a specific addition for the use of oats. Oats must have been specially produced and 94 processed in a way that avoids contamination by gluten-containing cereals and the maximum of 20 ppm gluten is 95 still valid. The US adopted a legislation on gluten and gluten-free products in 2013. According to this legislation 96 and contrary to the European legislation, the gluten-free label may also be applied to food that does not contain a 97 gluten-containing grain, including naturally gluten-free foods, as long as the gluten content of the final product 98 does not exceed 20 ppm (U.S. Food and Drug Administration, 2013) . The Canadian legislation differs from both 99 the European and American legislation by stating that gluten-free products can not contain wheat, including spelt 100 and kamut, or oats, barley, rye, triticale, or any part thereof (Canadian Food and Drug Regulations, 2013) . In this 101 case, the 20 ppm threshold is used to set a maximum level of allowed cross-contamination with gluten.
102
The gluten legislation of Australia and New Zealand is very different from the abovementioned gluten after processing could be labelled gluten-free in the US and in Europe, but not in Canada and Australia. A 122 naturally gluten-free food such as milk can be labelled gluten-free in the US, but not in Europe. In addition to 123 gluten-free labels, 'low in gluten', 'very low in gluten' and 'may contain' labels are used as well. For CD 124 patients, these different labels can be confusing as all that really matters to them is whether or not a product is 125 safe for them to eat. The gluten thresholds have been and still are under much debate. The bottom line is that 126 these labels should allow CD patients to make safe food choices. When looking at the legislations above, four 127 different thresholds can be distinguished: (a) No detectable gluten (which currently translates into < 3 ppm 
Exposure
132
The gluten-free diet consists of a combination of naturally gluten-free foods such as fruits, vegetables, meat, fish,
133
eggs and dairy products with gluten-free substitutes for cereal-based foods such as bread and pasta. For most 134 naturally, non-processed gluten-free foods such as fruit and eggs, the chance of cross-contamination with gluten 135 is small. Cross-contamination of gluten-free cereals and, as a result, products made from these cereals is much 136 more common. Also naturally gluten-free foods that are processed, such as lunch meats, are often prone to cross-137 contamination if gluten-containing products are processed on the same locations. The total amount of gluten that 138 CD patients are exposed to depends on both the gluten contents of the products that they consume and the 139 amount of product consumed.
141
Gluten content of foods
142
Thompson and Grace evaluated the gluten content of 112 food products labelled gluten-free, using a R5 ELISA 143 (Thompson & Grace, 2013) . Four products (i.e. bread, hot cereal, tortilla, cookie) contained 20 ppm gluten or 144 more, although the exact gluten contents above 20 ppm were not reported. Gibert et al used a R5 ELISA to 145 determine the gluten content of 205 commercially available products labelled gluten-free (Gibert, et al., 2013) .
146
One pastry product contained more than 20 ppm gluten; namely 27.8 ppm. In 191 of the 205 products, no gluten prospective trial to establish a safe gluten threshold and did a background analysis on the gluten-free products 155 consumed by the patients in their study (Catassi, et al., 2007) . A total of 42 commercially available gluten-free 156 products, randomly chosen from the dietary assessment of the patients, was analysed with a R5 ELISA. The 157 gluten content of these products was found to range from < 3-50 ppm, with an average of 5.2 ppm.
158
Unfortunately, the exact number of products with a gluten content above 20 ppm is not given. Collin et al 159 compared the gluten content of 46 naturally gluten-free flours and 13 naturally gluten-free products with 17 160 wheat starch-based flours and 7 wheat starch-based products (Collin, Thorell, Kaukinen, & Mäki, 2004) .
161
Analysis was performed with a R5 ELISA. In the naturally gluten-free group, 35 flours (76%) and 11 products 
Consumption
170
Gluten exposure for CD patients is not only dependent on the amount of gluten present in their foods, but also on 171 the amount of products consumed by these patients. Catassi et al kept records of the daily consumption of 172 commercially available gluten-free products consumed by the patients in their study (Catassi, et al., 2007) . The 173 type of products were not specified, but the average daily consumption of the CD patients was 332 g (range 177- Norway (Gibert, et al., 2006) . Gluten-free bread was the most consumed gluten-free product in all four countries 178 and together with pasta this made up to 64%, 56%, 71% and 71% of the total daily intake, respectively. Other 179 gluten-free substitute products that were consumed often included pastry, biscuits and breakfast cereals. The 180 total daily intake of gluten-free products at the 90 th percentile of the studied population was 400-411 g/day in M A N U S C R I P T
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Tolerable levels
185
In order to set a proper threshold for gluten, the amount of gluten that is tolerated by CD patients needs to be 186 known. These exact amounts can differ per person, but in general three groups of CD patients with different 187 needs can be distinguished: the average CD population; the sensitive CD population; and the recovering CD 188 population. Table 1 gives an overview of the studies included in this paper. Specific information on the tolerable 189 levels of gluten intake derived from these studies is given in Table 2 .
190
Depending on the study, the gluten contents were assessed differently. This influences the accuracy of 191 the reported amounts of gluten to which the patients were exposed. The studies performed by Chartrand et al, wheat starches will contain the maximum allowed amount of gluten. However, it is also possible that the wheat 199 flour in these studies contained more than the maximum allowed amount of gluten, which would lead to an gluten/day can be tolerated by most CD patients (Catassi, et al., 2007) . In the same study, a dose of 50 mg M A N U S C R I P T
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8 gluten/day was found to cause mucosal atrophy. Troncone et al saw a histological relapse in some patients who 212 were exposed to 60 mg gluten/day (Troncone, Mayer, Spagnuolo, Maiuri, & Greco, 1995) . Studies examining 213 the effects of 200 mg gluten/day or more, all found that these amounts are harmful to CD patients (Catassi, et al., 214 1993; Greco, et al., 2011; Laurin, Wolving, & Fälth-Magnusson, 2002; Srinivasan, et al., 1996) . Several groups 215 determined the gluten content of wheat starch, which is already used in the gluten-free diet of many patients.
216
Some wheat starch products contain up to 200 ppm gluten. An estimation of the gluten exposure for CD patients 217 using these products can be made by looking at the average and maximum intake. In three separate studies, the 218 average intake of gluten via these contaminated wheat starch products was below 50 mg/day (Collin, et al., 2004; 219 Kaukinen, et al., 1999; Lohiniemi, Mäki, Kaukinen, Laippala, & Collin, 2000) . Although all three studies 220 reported some CD patients with histological changes, these changes could not be correlated to the amount of 221 wheat starch used. These results would suggest that the tolerable level of gluten for most CD patients lies 222 between 10-50 mg/day.
224
Sensitive CD population
225
For part of the CD population however, a gluten intake of 10 mg/day seems to be too much. In the study by
226
Catassi et al, one participant out of a group of fifteen receiving 10 mg gluten/day quit the study due to relapse 227 symptoms (Catassi, et al., 2007) . In the study of Chartrand et al, 17 CD patients were exposed to 0. Fasano, 2013). After these patients had followed a diet without all gluten-free food products with a high risk of 248 being contaminated by gluten for at least 3 months, 13 out of 16 patients (81%) became asymptomatic. Of this 249 group, 79% remained symptom-free after returning to a traditional gluten-free diet. This indicates that at least 250 part of the recovering CD population has lower tolerance levels for gluten than they will have after they have 251 been fully recovered. For these persons, an exposure of 10 mg gluten/day as mentioned above may be too much 252 to be exposed to as long as they are recovering from previous gluten intake.
254
Thresholds evaluation
255
To evaluate the current thresholds for gluten, it is important to compare the amount of gluten that CD patients 256 would be exposed to, to the amount of gluten that can be tolerated. The amount of gluten exposure is dependent 257 on the amount of intake of gluten-free products and the maximum gluten content of these products, as shown in 258   Table 3 (adapted from Collin, et al. (2004) ). As discussed above, the total intake of gluten-free products per day 259 would on average be between 300 and 400 g for most CD patients, with some individuals consuming up to 600 260 g. With the Australian threshold of < 3 ppm, patients would on average be exposed to 0.9-1.2 mg gluten/day, up 261 to 1.8 mg gluten/day. In other countries in which the threshold is currently 20 ppm, patients would on average be 262 exposed to 6-8 mg gluten/day, up to 12 mg gluten/day, given an average amount of gluten-free product 263 consumption up to 600 g. As shown above, an intake of 10 mg gluten/day was safe for most CD patients. The 264 studies that assessed the gluten content of wheat starch found that on average, a CD patient using 70-80 g wheat 265 starch per day is exposed to 16-36 mg gluten/day. This shows that at least a part of the average CD population 266 could tolerate more than 10 mg gluten/day, assuming that they are not in the process of recovering anymore.
267
However, there is also a group of sensitive CD patients that do show signs of inflammation after consuming 10 268 mg gluten/day or less, starting at 0.75 mg/day. This group is not protected by the threshold of 20 ppm. For them, 269 a gluten threshold at the limit of detection, 3 ppm, would allow them to safely eat up to 250 g gluten-free 270 product. The group of CD patients that is still recovering, would also be helped by a lower gluten threshold than M A N U S C R I P T
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10 20 ppm. Therefore, for this group a gluten threshold of 3 ppm would also be more suitable. Once full recovery 272 has been achieved, most of these patients will be able to consume the same kind and amount of products as the 273 average CD population.
274
'Very low in gluten' products can contain up to 100 ppm gluten, which implies that CD patients with a 275 total product consumption of 300-400 g/day would be exposed to 30-40 mg gluten/day. Patients with a high 276 product intake would be exposed to 60 mg/day. No data is available for the 30-50 mg/day range, but intake of 50 277 mg gluten/day caused villous atrophy in the majority of CD patients (Catassi, et al., 2007) . Therefore, patients 278 with a high consumption of 'very low in gluten' products would be exposed to unsafe amounts of gluten.
279
Patients consuming products 'low in gluten' would be exposed to even higher amounts of gluten, as the 280 thresholds for these products is 200 ppm gluten. In that case, patients with an average product intake of 300-400 281 g/day would be exposed to 60-80 mg gluten/day, up to 120 mg/day for patients daily consuming up to 600 g 282 products. This is more than twice the amount known to cause villous atrophy. These results show that the current 283 thresholds of both the 'very low in gluten' and 'low in gluten' products are too high for CD patients to safely 284 consume these products. The 'low in gluten' label is irrelevant and harmful for CD patients when misinterpreted 285 and should, therefore, be withdrawn. To make the 'very low in gluten' label meaningful again, it should be based 286 on gluten content that is safe for CD patients to consume after the mucosa has been recovered from previous (1996) Cross-sectional study, Ireland Adults, 2 6 weeks -500 mg gluten/day -Both patients developed histological evidence of relapse Troncone, et al.
Cross-sectional study, Italy
Adolescents, 23 >10 years -Strict gluten-free diet -<0.5 g gluten/day -0.5-2 g gluten/day ->2 g gluten/day -Changes in mucosal architecture in 0%, 50%, 83% and 100%, respectively Catassi, et al.
Randomized controlled trial, Italy
Children, 20 4 weeks -100 mg gliadin/day -500 mg gliadin/day -Minimal morphometric changes in jejunal histology for 100 mg/day -Profound morphometric changes in jejunal histology for 500 mg/day M A N U S C R I P T Greco, et al. (2011) -496 mg gluten/day results in mucosal atrophy -1.6 mg gluten/day is safe Catassi, et al. (2007) -50 mg gluten/day results in mucosal atrophy -10 mg gluten/day is safe for most CD patients Biagi, et al. (2004) -1 mg gluten/day leads to persisting villous atrophy Collin, et al. (2004) -in the worst case scenario, CD patients are already exposed up to 60 mg gluten/day -on average, CD patients are already exposed up to 16 mg gluten/day Laurin, et al. (2002) -200 mg gluten/day results in CD symptoms Lohiniemi, et al. (2000) -in the worst case scenario, CD patients are already exposed to 180 mg gluten/day -on average, CD patients are already exposed to 36 mg gluten/day Kaukinen, et al. (1999) -in the worst case scenario, CD patients are already exposed to 150 mg gluten/day -on average, CD patients are already exposed to 34 mg gluten/day Chartrand, et al. (1997) -0.75 mg gluten/day results in CD symptoms Srinivasan, et al. (1996) -500 mg gluten/day results in histological relapse Troncone, et al. (1995) -60 mg gluten/day results in histological relapse in some Catassi, et al. (1993) -200 mg gluten/day results in histological relapse M A N U S C R I P T A C C E P T E D Table 3 : Estimated amount of daily gluten exposure (mg).
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14
390
Amount of gluten-free products consumed (g) Gluten content of glutenfree products (ppm)   100  200  300  400  500  600   200  20  40  60  80  100  120  100  10  20  30  40  50  60  50  5  10  15  20  25  30  40  4  8  12  16  20  24  30  3  6  9  12  15  18  20  2  4  6  8  10  12  10  1  2  3  4  5  6  5 0.5 1 1.5 2 2.5 3 3 a 0.3 0.6 0.9 1.2 1.5 1.8 a Considered the lowest limit of detection for gluten at this moment.
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